MLchartDataset catalogue

TRAC locus integrated anti-CD19 19(T2)28z1xx CAR-T cells

Term · Oncology and biomedicine · MLC-T-ONC-017286

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), and inserted into the T-cell receptor alpha constant (TRAC) locus, with potential immunostimulating and antineoplastic activities. Upon administration, the TRAC locus integrated anti-CD19 19(T2)28z1xx CAR-T cells specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. CD28 and CD3zeta provide co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T cells. The 19(T2)28z1xx CAR includes a 1928zeta mutant, 1xx, which contains one instead of all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation and exhaustion. Integrating the anti-CD19 CAR to the TRAC locus may enhance both T-cell potency and the re-expression of the CAR following exposure to antigen.

Table 1. Record
IdentifierMLC-T-ONC-017286
FieldOncology and biomedicine
Synonyms19(T2)28z1xx TRAC T cells; 19(T2)28z1xx TRAC-CAR T cells; TRAC locus integrated CD19-targeted CAR T cells
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-017286",
  "term": "TRAC locus integrated anti-CD19 19(T2)28z1xx CAR-T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), and inserted into the T-cell receptor alpha constant (TRAC) locus, with potential immunostimulating and antineoplastic activities. Upon administration, the TRAC locus integrated anti-CD19 19(T2)28z1xx CAR-T cells specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. CD28 and CD3zeta provide co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of the CAR T cells. The 19(T2)28z1xx CAR includes a 1928zeta mutant, 1xx, which contains one instead of all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation and exhaustion. Integrating the anti-CD19 CAR to the TRAC locus may enhance both T-cell potency and the re-expression of the CAR following exposure to antigen.",
  "synonyms": [
    "19(T2)28z1xx TRAC T cells",
    "19(T2)28z1xx TRAC-CAR T cells",
    "TRAC locus integrated CD19-targeted CAR T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/trac-locus-integrated-anti-cd19-19-t2-28z1xx-car-t-cells/"
}

Record 16,577 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.